ResMed (RMD) to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is expected to be announcing its earnings results after the market closes on Thursday, January 30th. Analysts expect the company to announce earnings of $2.29 per share and revenue of $1,271,075.38 billion for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.17. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.64 earnings per share. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Trading Down 0.2 %

Shares of RMD stock opened at $247.36 on Thursday. The company has a market capitalization of $36.31 billion, a PE ratio of 32.76, a price-to-earnings-growth ratio of 1.73 and a beta of 0.70. The firm has a 50 day moving average price of $238.35 and a two-hundred day moving average price of $233.80. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. ResMed has a 12-month low of $170.56 and a 12-month high of $260.49.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Bank of America lifted their price objective on shares of ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Stifel Nicolaus started coverage on ResMed in a research note on Friday, December 13th. They issued a “hold” rating and a $250.00 price target on the stock. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They issued a “buy” rating for the company. Finally, Royal Bank of Canada lifted their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $233.09.

Insider Activity at ResMed

In related news, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the transaction, the director now owns 83,204 shares in the company, valued at $20,696,162.96. This represents a 2.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,099 shares of company stock worth $2,719,385 in the last quarter. Company insiders own 0.71% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.